SOPHARMA AD - Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals

POLISH FINANCIAL SUPERVISION AUTHORITY

UNI - EN REPORT No 58 / 2017

Date of issue: 2017-08-02

Short name of the issuer

SOPHARMA AD

Subject

Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals

Official market - legal basis

art. 17. 1 MAR.

Unofficial market - legal basis

Contents of the report:

Sopharma AD notifies that the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals was successfully closed today and as a result of which the stockholders of Achieve have become the majority stockholders of OncoGenex. OncoGenex has been renamed Achieve Life Sciences (NASDAQ: ACHV). The company announced that "Cytisine is a drug of global public health importance and the transition of Achieve to the public markets is a critical step in advancing our development program,” commented Rick Stewart, Chairman and CEO of Achieve Life Science. The whole press release may be found at http://ir.oncogenex.com/releasedetail.cfm?ReleaseID=1030091.

Annexes

File Description

3JR_Notification_Achieve_02082017.doc Notification for the merger between Achieve Life Sciences, Inc. and OncoGenex Pharmaceuticals

SOPHARMA AD

(fullname of the issuer)

SOPHARMA AD Farmaceutyczny (far)

(short name of the issuer) (sector according to clasification of the WSE in Warsow)

1220 Sofia

(post code) (city)

IlienskoShosse 16

(street) (number)

[phone] [phone]

(phone number) (fax)

(e-mail) (web site)

nd

(NIP) (REGON)

SIGNATURE OF PERSONS REPRESENTING THE COMPANY

Date Name Position / Function Signature

2017-08-02 Ognian Donev Executive director